Cognitive Markers of Response to Treatment in Resistant Depression

Centre Hospitalier Universitaire de Nice30 enrolled

Overview

Patients with depression are frequently treatment resistant. Clinical manifestations of depression are various, but cognitive dysfunctions are commonly present. Many factors are involved in treatment resistance. As no biological marker is available, clinical markers could be considered in predicting response to antidepressive treatment. The aim of this study is to investigate the relation between the cognitive changes and the remission of depressive symptoms in patients with recurrent depression (Stage 2 of Thase and Rush classification). To explore the dynamics of cognitive dimension associated to clinical and functional remission, the investigators will observe neurocognitive functioning before and after introducing a new antidepressive therapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Depression

Interventions

Recurrent depressionBEHAVIORAL

Eligibility

Sex: ALLMin age: 40 Years

Outcomes

Primary Outcomes

Clinic assessments: Score BDI - II

The investigators will conduct clinical assessments. A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; 2 weeks after treatment change, patient will be clinically assessed by his psychiatrist. A complete assessment will be done 6 months and 12 months after introducing the new therapy.

Time frame: Change from the baseline score BDI-II at 12 months after introducing the new therapy

Functional assessments : Score Sheehan Disability Scale (SDS)

The investigators will conduct functional assessments. A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; 2 weeks after treatment change, patient will be functional assessed by his psychiatrist. A complete assessment will be done 6 months and 12 months after introducing the new therapy.

Time frame: Change from the baseline Score Sheehan Disability Scale (SDS) at 12 months after introducing the new therapy

Neuropsychologic assessments: M.M.S.E. (Mini Mental Score Evaluation)

The investigators will conduct neuropsychologic assessments. A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; A complete assessment will be done 6 months and 12 months after introducing the new therapy.

Time frame: Change from the baseline Score M.M.S.E. (Mini Mental Score Evaluation) at 12 months after introducing the new therapy